Logo Logo
Switch Language to German
Sabet, Amir; Haug, Alexander R.; Eiden, Collin; Auernhammer, Christoph J.; Simon, Birgit; Bartenstein, Peter; Biersack, Hans J.; Ezziddin, Samer (2017): Efficacy of peptide receptor radionuclide therapy with Lu-177-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. In: American Journal of Nuclear Medicine and Molecular Imaging, Vol. 7, No. 2: pp. 74-83
Full text not available from 'Open Access LMU'.


There is lack of data on the specific benefit of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) of pulmonary origin. This dual-centre study aimed to assess outcome and toxicity of standardized PRRT with Lu-177-octreotate in a patient population of advanced pulmonary NET of grade 1-2. We retrospectively assessed 22 consecutively patients treated with 4 intended cycles at 3 monthly intervals (mean activity per cycle 7.8 +/- 0.68 GBq). In a median follow-up period of 54 months, no significant nephrotoxicity (>= grade 3) was observed. Reversible hematotoxicity (grade 3) occurred in 3 patients (13.6%). Treatment response consisted of partial response in 6 (27.3%), stable disease in 9 (40.9%), and progressive disease in 7 (31.8%) patients. Median progression-free survival (PFS) and overall survival (OS) was 27 (95% Cl, 9-45) and 42 months (95% Cl, 25-59), respectively. High hepatic tumor load (> 50%) and high plasma chromogranin A (> 600 ng/mL) were negative baseline predictors for PFS and OS on univariate analysis, CgA remained significant on multivariate analysis (PFS, P=0.011;OS, P=0.026). Disease progression despite PRRT was associated with shorter survival (median OS 15 vs 53 mo, P<0.001). Despite a higher incidence of treatment failure compared to NET of other origins, the observed substantial and sustained disease stabilization (median PFS of 27 mo, disease control rate of > 2/3 of pts) indicates considerable efficacy of 177Lu-octreotate in pulmonary NET.